(Q41932967)

14 October 2017

Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study (English)

1 reference

Marga van de Vegte-Bolmer

14 October 2017

0 references

10

object named as

Marga van de Vegte-Bolmer

1 reference

14 October 2017

14

Robert W Sauerwein

1 reference

14 October 2017

1

Meta Roestenberg

1 reference

14 October 2017

4

Karina Teelen

1 reference

14 October 2017

13

Cornelus C Hermsen

1 reference

14 October 2017

11

André J A M van der Ven

1 reference

14 October 2017

2

Anne C Teirlinck

1 reference

14 October 2017

Matthew B B McCall

3

1 reference

14 October 2017

Krystelle Nganou Makamdop

5

1 reference

14 October 2017

Jorien Wiersma

6

1 reference

14 October 2017

Theo Arens

7

1 reference

14 October 2017

Pieter Beckers

8

1 reference

14 October 2017

GeertJan van Gemert

9

1 reference

14 October 2017

Adrian J F Luty

12

1 reference

14 October 2017

language of work or name

English

0 references

publication date

22 April 2011

1 reference

14 October 2017

1 reference

14 October 2017

377

1 reference

14 October 2017

9779

1 reference

14 October 2017

1770-1776

1 reference

The economic burden of malaria.

14 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Cost effectiveness analysis of strategies to combat malaria in developing countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Acquired immunity to malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Advances and challenges in malaria vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Protection against a malaria challenge by sporozoite inoculation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Cardiac complication after experimental human malaria infection: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Does malaria suffer from lack of memory?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Is immunity to malaria really short-lived?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Immunity to malaria: more questions than answers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

A systematic map of genetic variation in Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Placental Plasmodium falciparum infection: causes and consequences of in utero sensitization to parasite antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Empowering malaria vaccination by drug administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Interferon-γ--central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

Experimental human challenge infections can accelerate clinical malaria vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960360-7

7 January 2021

10.1016/S0140-6736(11)60360-7

Identifiers

DOI

1 reference

14 October 2017

1 reference